Back to Journals » Drug Design, Development and Therapy » Volume 11

The new era of nanotechnology, an alternative to change cancer treatment

Authors Jurj A, Braicu C, Pop LA, Tomuleasa C, Gherman CD, Berindan-Neagoe I

Received 22 May 2017

Accepted for publication 26 July 2017

Published 27 September 2017 Volume 2017:11 Pages 2871—2890


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Rammohan Devulapally

Peer reviewer comments 3

Editor who approved publication: Dr Georgios Panos

Ancuta Jurj,1 Cornelia Braicu,1 Laura-Ancuta Pop,1 Ciprian Tomuleasa,1,2 Claudia Diana Gherman,3,4 Ioana Berindan-Neagoe1,5,6

1Research Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy “Iuliu-Hatieganu”, Cluj-Napoca, Romania; 2Department of Hematology, The Oncology Institute “Prof Dr Ion Chiricuta”, Cluj-Napoca, Romania; 3Practical Abilities, Department of Medical Education, University of Medicine and Pharmacy “Iuliu-Hatieganu”, Cluj-Napoca, Romania; 4Department of Medical Education, University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania; 5Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof Dr Ion Chiricuta”, Cluj-Napoca, Romania; 6MedFuture Research Center for Advanced Medicine, University of Medicine and Pharmacy “Iuliu-Hatieganu”, Cluj-Napoca, Romania

Abstract: In the last few years, nanostructures have gained considerable interest for the safe delivery of therapeutic agents. Several therapeutic approaches have been reported, such as molecular diagnosis, disease detection, nanoscale immunotherapy and anticancer drug delivery that could be integrated into clinical use. The current paper aims to highlight the background that supports the use of nanoparticles conjugated with different types of therapeutic agents, applicable in targeted therapy and cancer research, with a special emphasis on hematological malignancies. A particular key point is the functional characterization of nonviral delivery systems, such as gold nanoparticles, liposomes and dendrimers. The paper also presents relevant published data related to microRNA and RNA interference delivery using nanoparticles in cancer therapy.

Keywords: nanotechnology, gold nanoparticles, liposomes, dendrimers, microRNA, RNA interference

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples

Braicu OL, Budisan L, Buiga R, Jurj A, Achimas-Cadariu P, Pop LA, Braicu C, Irimie A, Berindan-Neagoe I

OncoTargets and Therapy 2017, 10:4225-4238

Published Date: 28 August 2017

Future trends and emerging issues for nanodelivery systems in oral and oropharyngeal cancer

Irimie AI, Sonea L, Jurj A, Mehterov N, Zimta AA, Budisan L, Braicu C, Berindan-Neagoe I

International Journal of Nanomedicine 2017, 12:4593-4606

Published Date: 26 June 2017

Epigallocatechin-3-gallate suppresses cell proliferation and promotes apoptosis and autophagy in oral cancer SSC-4 cells

Irimie AI, Braicu C, Zanoaga O, Pileczki V, Gherman C, Berindan-Neagoe I, Campian RS

OncoTargets and Therapy 2015, 8:461-470

Published Date: 20 February 2015

Clinical and pathological implications of miRNA in bladder cancer

Braicu C, Cojocneanu-Petric R, Chira S, Truta A, Floares A, Petrut B, Achimas-Cadariu P, Berindan-Neagoe I

International Journal of Nanomedicine 2015, 10:791-800

Published Date: 20 January 2015